French pharmaceutical company Ipsen will pay the Salk Institute for Biological Studies $10 million in the next three to five years to support key research initiatives that could boost the drug company’s pipeline.
La Jolla-based Salk announced the partnership Jan. 11.
The partnership marked the first time the nonprofit Salk agreed to accept money from a for-profit entity, although its scientists have entered into separate deals with for-profit companies in the past.
The funds, which will create the Ipsen Life Sciences Program, have three components. A target grant, about $750,000 a year, will support research in pituitary adenomas, or tumors that occur in the pituitary gland.
A core grant, about $1.25 million a year, will support the study of the role of inflammation in the onset of disease. Scientists have linked chronic inflammation to malignant diseases such as cancer, loss of cognitive functions, movement disorders and metabolic syndromes.
Innovation grants, about $500,000 a year, will fund the exploration of advanced scientific concepts.
Ipsen, which describes itself as a midsized specialty pharmaceutical company, has been operating in the United States since 1976 and has offices worldwide. Its research center near Boston specializes in protein and peptide research.
, Heather Chambers